Sorafenib tosylate (Bio-Synectics)

甲苯磺酸索拉非尼 (Bio-Synectics)

Report date: 2026/02/11 09:42:26

Base Information

Drug NameSorafenib tosylate (Bio-Synectics)
Drug Alias NameBS-104
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVascular endothelial growth factor receptor 3 antagonistsSerine/threonine-protein kinase B-raf inhibitorsVascular endothelial growth factor receptor 1 antagonists +[9] 
TargetsVascular endothelial growth factor receptor 1Stem cell growth factor receptorVascular endothelial growth factor receptor 3 +[9] 
Therapy Area/IndicationsN/A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaN/A
Originator CompaniesBio-Synectics Inc
China Registration ClassN/A

Develop Information

Active CompaniesBio-Synectics Inc
Inactive CompaniesN/A
Active IndicationsN/A
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A